Interaction of pemetrexed disodium (ALIMTA, multitargeted antifolate) and irradiation in vitro

International Journal of Radiation Oncology Biology Physics

Volumn 52, Issue 5, 2002, Pages 1381-1388

  Bischof, Marc ^a   Weber, Klaus Josef ^a   Blatter, Johannes ^b   Wannenmacher, Michael ^a   Latz, Detlev ^c  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b LILLY DEUTSCHLAND GMBH   (Germany)

^c KLINIKUM COBURG   (Germany)

Author keywords

Alimta; Cell cycle; Multitargeted antifolate; Pemetrexed disodium; Radiation

Indexed keywords

CELLS; ENZYMES; IONIZING RADIATION;

RADIOSENSITIZATION;

IRRADIATION;

FOLIC ACID ANTAGONIST; PEMETREXED; THYMIDYLATE SYNTHASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL KILLING; CELL LINE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; RADIATION RESPONSE; RADIOSENSITIZATION; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL SURVIVAL; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; FOLIC ACID ANTAGONISTS; GLUTAMATES; GUANINE; HUMANS; TUMOR CELLS, CULTURED;

EID: 0036535537     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(01)02794-8     Document Type: Article

References (35)

1. LY231514, a novel pyrrolopyrimidine antifolate that inhibits thymidylate synthase
2. LY231514, a pyrrolo[2,3-d]pyrimidine based antifolate that inhibits multiple folate requiring enzymes
3. Activity of LY231514 against several enzymes in the folate-dependent pathways
4. Enzyme inhibition, polyglutamation and the effect of LY231514 (MTA) on purine biosynthesis
5. Multiple folate enzyme inhibition; Mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA)
6. Overview of phase II trials of MTA in solid tumors
7. Studies on fluorinated pyrimidines. II. Effects of transplanted tumors
8. The use of radiation therapy combined with chemotherapy in the management of squamous cell carcinoma of the anus and marginally resectable adenocarcinoma of the rectum
9. Improving adjuvant therapy for rectal cancer by combining protracted infusion fluorouracil with radiation therapy after curative surgery
10. Interaction of Tomudex with radiation in vitro and in vivo
11. Mean inactivation dose; A useful concept for intercomparison of human cell survival curves
12. Radiosensitizing potential of gemcitabine (2′,2′-difluoro-2′-deoxycytidine) within the cell cycle in vitro
13. Exploitable mechanisms in combined radiotherapy-chemotherapy; The concept of additivity
14. Combined effects of ionizing irradiation and 4-hydroperoxyifosfamide in vitro
15. Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro to combined 5-fluoruracil or ftorafur and X rays
16. Fluoropyrimidine-radiation interactions in cells and tumors
17. Radiosensitization of cultured human colon adenocarcinoma cells by 5-fluoruracil; Effects on cell survival, DNA repair, and cell recovery
18. Fluorodeoxyuridine-induced radiosensitization and inhibition of DNA double strand break repair in human colon cancer cells
19. 5-fluorouracil-radiation interactions in human colon adenocarcinoma cells
20. Dependence of 5-fluorouracil-mediated radiosensitization on DNA-directed effects
21. A phase I evaluation of LY231514, a novel multitargeted antifolate, administered every 21 days
22. Overview of phase I trials of multitargeted antifolate (MTA, LY231514)
23. MTA (LY231514) in combination treatment regimens using human tumor xenografts and the EMT-6 murine mammary carcinoma
24. Transcription of the human foly-poly-glutamate synthetase gene
25. Modulation of antimetabolite effects; Effects of thymidine on the efficacy of the quinazoline based thymidylate synthetase inhibitor CB3717
26. MTA. Summary and conclusions
27. Tumor retention of 5-floururacil following irradiation observed using 19F nuclear magnetic resonance spectroscopy
28. Fluorodeoxyuridine-mediated cytotoxicity and radiosensitization require S phase progression
29. The role of cell cycle redistribution in radiosensitization; Implications regarding the mechanism of fluorodeoxyuridine radiosensitization
30. DNA breakage and repair
31. DNA double-strand break repair in mammalian cells
32. Evidence for DNA PK-dependent and -independent DNA double-strand repair pathways in mammalian cells as a function of the cell cycle
33. Functional folate status as a prognostic indicator of toxicity in clinical trials of the multitargeted antifolate LY231514
34. An overview of folate metabolism; Features relevant to the action and toxicities of antifolate anticancer agents
35. LY231514 (MTA); Relationship of vitamin metabolite profile to toxicity